Viking Therapeutics enters into collaboration for novel THRB agonists for X-ALD

Viking Therapeutics has entered into a research collaboration agreement with the Academic Medical Center (AMC) of the University of Amsterdam in the Netherlands. The collaboration will focus on the development of the company's proprietary selective *thyroid hormone receptor beta (THRB) agonists* as potential treatments for X-linked adrenoleukodystrophy (X-ALD) and related diseases.

Under the terms of the agreement, Viking will provide financial support and access to its proprietary library of thyroid hormone receptor beta agonists for scientists at AMC to evaluate in preclinical models of the disease. Viking will own exclusive rights to all research and associated intellectual property resulting from the collaboration, while AMC will have the ability to publish results, subject to Viking's consent (Viking Therapeutics News Release).